2022 Webinar: Non-Invasive Assessment of Clinically Significant Poral Hypertension

Product not yet rated

There is emerging data showing benefits of diagnosing clinically significant portal hypertension and its treatment to prevent decompensation. The field is rapidly evolving, specifically with respect to non-invasive modalities of measurement. This webinar will review currently available non-invasive tests to measure clinically significant portal hypertension including blood tests, liver stiffness and spleen stiffness. Use of non-invasive measurements in special populations such as those with fatty liver disease and those who have achieved sustained virological response as well as how to monitor improvements in clinically significant portal hypertension without ongoing injury are also areas of interest which will be addressed.

There will then be a 20-minute discussion between panelists and a Q and A session to involve the audience, directed by our moderator.

Maja Thiele, MD, PhD

Dr. Maja Thiele works to reduce morbidity and mortality from alcohol-related liver disease, for the benefit of an otherwise stigmatized patient group. Her research centers on the development and validation of diagnostic and prognostic biomarkers, with a particular focus on early disease detection, cost-effective referral pathways and omics technologies. Elastography expert contributor to EASL Clinical Practice Guidance, the BAVENO VII consensus statement, and AASLD clinical guidance. Partner in the European research consortia GALAXY, LiverScreen, MicrobPredict and SALVE.

Annalisa Berzigotti

Annalisa Berzigotti graduated in Medicine in Bologna, Italy, where she also obtained the title of specialist in Internal Medicine and a Doctorate in ultrasound in medicine. She expanded her knowledge in hepatology at the Hepatic hemodynamic Laboratory of the Liver Unit of the Hospital Clinic, University of Barcelona, Spain, where she obtained a Doctorate in hepatology. In December 2014 she joined the hepatology group of the Department of Visceral Surgery and Medicine, Bern University Hospital, University of Bern, Switzerland. Since March 2021 she is chief of the liver group and ad interim clinic director at the Department of Visceral Surgery and Medicine, Bern University Hospital.  Annalisa Berzigotti has been member of the Governing Board of the European Association for the Study of the Liver in 2016-2019. Since 2022 she is Liver Representative at the United European Gastroenterology (UEG) Council. She is Associate Editor of the Journal of Hepatology and of Seminars in Liver Disease. Her main research interests include portal hypertension and non-invasive assessment of liver disease.

Atoosa Rabiee, MD

Annalisa Berzigotti graduated in Medicine in Bologna, Italy, where she also obtained the title of specialist in Internal Medicine and a Doctorate in ultrasound in medicine. She expanded her knowledge in hepatology at the Hepatic hemodynamic Laboratory of the Liver Unit of the Hospital Clinic, University of Barcelona, Spain, where she obtained a Doctorate in hepatology. In December 2014 she joined the hepatology group of the Department of Visceral Surgery and Medicine, Bern University Hospital, University of Bern, Switzerland. Since March 2021 she is chief of the liver group and ad interim clinic director at the Department of Visceral Surgery and Medicine, Bern University Hospital.  Annalisa Berzigotti has been member of the Governing Board of the European Association for the Study of the Liver in 2016-2019. Since 2022 she is Liver Representative at the United European Gastroenterology (UEG) Council. She is Associate Editor of the Journal of Hepatology and of Seminars in Liver Disease. Her main research interests include portal hypertension and non-invasive assessment of liver disease.

Key:

Complete
Failed
Available
Locked
Non-invasive Assessment of Clinically Significant Portal Hypertension
Select the "View On-Demand Recording" button to begin.
Select the "View On-Demand Recording" button to begin. There is emerging data showing benefits of diagnosing clinically significant portal hypertension and its treatment to prevent decompensation. The field is rapidly evolving, specifically with respect to non-invasive modalities of measurement. This webinar will review currently available non-invasive tests to measure clinically significant portal hypertension including blood tests, liver stiffness and spleen stiffness. Use of non-invasive measurements in special populations such as those with fatty liver disease and those who have achieved sustained virological response as well as how to monitor improvements in clinically significant portal hypertension without ongoing injury are also areas of interest which will be addressed. There will then be a 20-minute discussion between panelists and a Q and A session to involve the audience, directed by our moderator.
Final Evaluation
Post Webinar Survey
13 Questions
13 Questions Thank you for attending the Leveling the Playing Field: Promoting Women in Academia webinar hosted by the Women's Initiative Committee on Tuesday, December 13, 2022. We greatly appreciate your feedback to continue providing quality hepatology education.